| NCT00229658An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes | Pramlintide Type 1 diabetes, Type 2 diabetes | HbA1c ≤9% | — | Completed | 107 | May 2008 | 1 | results |
| NCT00108004Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus | Pramlintide Type 1 diabetes, Type 2 diabetes | HbA1c 7-11% | Ph 3 | Completed | 48 | Jun 2005 | 3 | |
| NCT00467649A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes | Pramlintide Obesity / overweight, Type 2 diabetes | BMI 25-50 | Ph 4 | Completed | 37 | Apr 2008 | 1 | results |
| NCT00673387Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects | Pramlintide Obesity / overweight | BMI 30-35 | Ph 2 | Completed | 36 | Apr 2009 | 1 | results |
| NCT00240253A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes | Pramlintide Obesity / overweight, Type 2 diabetes | BMI 25-45 | Ph 4 | Completed | 34 | Jun 2006 | 3 | |
| NCT00042458Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control | Pramlintide Type 1 diabetes | HbA1c 7.5-9% | Ph 3 | Completed | 33 | Mar 2003 | 1 | |
| NCT00819234Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin | Pramlintide Obesity / overweight | — | Ph 2 | Completed | 33 | Oct 2009 | 1 | results |
| NCT00107107Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | — | Ph 3 | Completed | 25 | Jun 2005 | 1 | |
| NCT00112021A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects | Pramlintide Obesity / overweight | BMI 30-50 | Ph 2 | Completed | 21 | Nov 2005 | 1 | |
| NCT00189514A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects | Pramlintide Obesity / overweight | — | Ph 2 | Completed | 21 | Jun 2007 | 1 | |
| NCT01235741A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects | Pramlintide Obesity / overweight | BMI 35-45 | Ph 2 | Terminated | 18 | Sep 2011 | — | results |
| NCT00402077A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | Pramlintide Obesity / overweight | BMI 30-50 | Ph 2 | Completed | 16 | Aug 2007 | — | |
| NCT00392925A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects | Pramlintide Obesity / overweight | BMI 30-35 | Ph 2 | Completed | 12 | Sep 2007 | 1 | results |
| NCT00444561Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects | Pramlintide Obesity / overweight | BMI 30-45 | Ph 2 | Completed | 10 | May 2005 | — | |
| NCT00042471Evaluation of the Bioavailability of Pramlintide | Pramlintide Obesity / overweight, Type 1 diabetes, Type 2 diabetes | BMI 30-45 | Ph 2 | Completed | 4 | Dec 2002 | — | |
| NCT01137695Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus | Pramlintide Obesity / overweight, Type 2 diabetes | BMI ≥30 | Ph 3 | Unknown | 3 | Jan 2012 | — | |
| NCT02500979Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | BMI ≤30 | Ph 1 | Completed | 3 | Aug 2016 | 1 | results |
| NCT00313183A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | HbA1c 6-10% | Ph 2 | Completed | 3 | Aug 2007 | — | |
| DTADMulti-Center Development of a Novel Diagnostic Test for Alzheimer's Disease | Pramlintide Alzheimer's / cognition, Healthy volunteers | BMI 20-35 | Early Ph 1 | Active, not recruiting | 3 | Nov 2026 | — | |
| APPPancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans | Pramlintide Healthy volunteers | BMI 18-27 | Not applicable | Recruiting | 1 | Oct 2026 | — | |
| NCT00206258The Role of Amylin and Glucagon in T1DM | Pramlintide Type 1 diabetes | HbA1c ≤8% | Ph 3 | Completed | 1 | Aug 2005 | 1 | |
| NCT00291772Continuous Subcutaneous Infusion of Pramlintide and Insulin | Pramlintide Type 1 diabetes | HbA1c ≤8.5% | Ph 4 | Completed | 1 | Nov 2007 | 2 | |
| NCT00442767Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | HbA1c ≤8.5% | Ph 4 | Completed | 1 | Feb 2009 | 1 | results |
| NCT00502138A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes | Pramlintide Type 1 diabetes | BMI ≤35 | Ph 4 | Completed | 1 | Jan 2008 | 1 | |
| NCT00690235Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia | Pramlintide Obesity / overweight, Psychiatric (schizophrenia / bipolar / depression) | BMI ≥27 | Ph 4 | Completed | 1 | Aug 2011 | — | results |
| NCT00691158A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide | Pramlintide Healthy volunteers, Obesity / overweight | — | Not applicable | Unknown | 1 | Jul 2024 | — | |
| NCT00790699Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port | Pramlintide Type 1 diabetes, Type 2 diabetes | HbA1c 6.5-9% | Not applicable | Terminated | 1 | Nov 2011 | — | results |
| NCT00842075Pramlintide in Adolescents With Type 1 Diabetes | Pramlintide Type 1 diabetes | HbA1c 7.5-10% | Not applicable | Completed | 1 | Dec 2009 | 1 | results |
| NCT01269047Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia | Exenatide, Pramlintide Type 1 diabetes | HbA1c ≤9% | Ph 4 | Completed | 1 | Aug 2016 | — | results |
| NCT01708044Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM | Pramlintide Type 1 diabetes | BMI ≤30 | Ph 1 | Completed | 1 | Sep 2013 | 1 | |
| NCT01841359Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery | Pramlintide Bariatric Surgery | — | Ph 4 | Completed | 1 | Jul 2016 | 5 | results |
| NCT02814123Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes | Pramlintide Type 1 diabetes | HbA1c ≤10% | Ph 2 | Completed | 1 | Jul 2018 | 2 | |
| DualInsulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting | Pramlintide Type 1 diabetes | HbA1c ≤12% | Ph 2 | Completed | 1 | Sep 2020 | 1 | |
| NCT03981627A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | HbA1c ≤9% | Ph 1/2 | Completed | 1 | Jun 2020 | 1 | |
| NCT04074317Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D | Pramlintide Type 1 diabetes | BMI 18-35 | Ph 2 | Completed | 1 | Apr 2020 | — | results |
| NCT04163874Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas | Pramlintide Type 1 diabetes | HbA1c ≤12% | Not applicable | Completed | 1 | Jan 2022 | 1 | |
| NCT06422325Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide | Pramlintide Type 1 diabetes | HbA1c ≤10.5% | Not applicable | Completed | 1 | Jan 2025 | — | results |
| TOTTTailoring Obesity Treatment Trial | Pramlintide, Semaglutide Obesity / overweight, Prediabetes / glucose intolerance | — | Ph 2/3 | Withdrawn | 1 | Apr 2025 | — | |
| NCT07340775Hypersensitivity to Amylin in Post-Traumatic Headache | Pramlintide Brain Injuries, Headache Disorders | — | Not applicable | Not yet recruiting | 1 | Dec 2028 | 7 | |
| NCT07340788Amylin-Induced Migraine Attacks Without Aura | Pramlintide Headache Disorders | — | Not applicable | Not yet recruiting | 1 | Oct 2028 | 8 | |
| NCT00042601Evaluation of the Effect of Pramlintide on Satiety and Food Intake | Pramlintide Healthy volunteers, Obesity / overweight, Type 1 diabetes, Type 2 diabetes | BMI 20-25 | Ph 2 | Completed | 1 | Oct 2003 | — | |
| NCT00044707Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide | Pramlintide Type 2 diabetes | HbA1c 6.5-11% | Ph 2 | Completed | 1 | Sep 2002 | — | |
| NCT00206297The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes | Pramlintide Type 1 diabetes | HbA1c ≤8.5% | Ph 3 | Completed | 1 | Feb 2006 | — | |
| NCT00505882Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes | Pramlintide Type 1 diabetes | HbA1c ≥7% | Ph 4 | Withdrawn | 1 | Dec 2008 | — | |
| T2DMThe Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes | Exenatide, Pramlintide Type 2 diabetes | HbA1c ≤8.5% | Ph 4 | Completed | 1 | May 2011 | — | |
| NCT01165944Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus | Pramlintide Diabetes (other / unspecified) | — | Ph 1/2 | Withdrawn | 1 | Aug 2011 | — | |
| ClosedloopClosed Loop System With Pramlintide Versus Exenatide | Exenatide, Pramlintide Type 1 diabetes | HbA1c ≤8.5% | Ph 1 | Completed | 1 | Jan 2013 | — | |
| ALM002Pramlintide Combined With Model Predictive Control Algorithm | Pramlintide Type 1 diabetes | HbA1c 7-9% | Not applicable | Terminated | 1 | Feb 2012 | — | |
| NCT01839370Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | HbA1c ≥6.5% | Not applicable | Completed | 1 | Nov 2013 | — | |
| NCT03512236A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | — | Ph 1 | Completed | 1 | Feb 2019 | — | |
| NCT03547427Glucagon Counterregulation in Type 1 Diabetes | Pramlintide Type 1 diabetes | HbA1c ≤10.5% | Not applicable | Terminated | 1 | Mar 2019 | — | |
| NCT03598075Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients | GLP-1 / incretin class catch-all, Pramlintide Headache Disorders | — | Not applicable | Completed | 1 | Sep 2019 | — | |
| NCT03916640A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus | Pramlintide Type 1 diabetes | BMI 18.5-28 | Ph 1 | Completed | 1 | Mar 2019 | — | |
| NCT03993366Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement | Pramlintide Type 1 diabetes | HbA1c ≤12% | Not applicable | Completed | 1 | Aug 2019 | — | |
| NCT04243629Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes | Pramlintide Type 1 diabetes | HbA1c ≤11% | Not applicable | Unknown | 1 | Apr 2024 | — | |
| NCT04252612Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | Pramlintide Oncology | — | Early Ph 1 | Withdrawn | 1 | Jun 2023 | — | |
| NCT04972175Safety and Efficacy of BC LisPram | Pramlintide Type 1 diabetes | HbA1c ≤9.5% | Ph 1 | Unknown | 1 | Jun 2022 | — | |
| FCLA Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes | Pramlintide Type 1 diabetes | — | Not applicable | Completed | 1 | Mar 2023 | — | |
| FCLA Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes | Pramlintide Type 1 diabetes | — | Ph 2/3 | Unknown | 1 | Apr 2025 | — | |
| AmyBoneThe Role of Amylin in Bone Metabolism | Pramlintide Healthy volunteers, Type 1 diabetes | BMI 18.5-27 | Not applicable | Unknown | 1 | Aug 2024 | — | |
| NCT00460304The Effect of Pramlintide on Meal Time Insulin Bolus | Pramlintide Type 1 diabetes | HbA1c ≤8.9% | Not applicable | Completed | 0 | Nov 2008 | 9 | |
| NCT00489645Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide | Pramlintide Healthy volunteers, Type 1 diabetes | Healthy volunteers | Not applicable | Completed | 0 | Mar 2007 | — | |
| NCT00732147Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM | Pramlintide Type 2 diabetes | BMI ≤52 | Not applicable | Withdrawn | 0 | Apr 2011 | — | |
